公开(公告)号：US20240148914A1

公开(公告)日：2024-05-09

申请号：US18219656

申请日：2023-07-08

Applicant: MICROVASCULAR THERAPEUTICS, LLC

Inventor： Evan C. Unger ,  Emmanuelle Joelle Meuillet ,  Iman Daryaei ,  Maria Fernanda Acosta

IPC: A61K49/22 ,  A61K41/00 ,  A61K47/10 ,  A61K47/26 ,  A61K47/51 ,  A61P7/02

CPC classification number: A61K49/223 ,  A61K41/0028 ,  A61K47/10 ,  A61K47/26 ,  A61K47/51 ,  A61K49/226 ,  A61P7/02

Abstract: The invention provides nanodroplets labeled with targeting ligands that are useful in the detection and treatment of vascular thromboses (e.g., fibrin clots) and vascular plaques, or related diseases and conditions, as well as methods of preparation and use thereof.

公开(公告)号：US20240033361A1

公开(公告)日：2024-02-01

申请号：US18265458

申请日：2021-10-28

Applicant: Yudai TABUCHI ,  Jay YANG ,  Masumi TAKI

Inventor： Yudai TABUCHI ,  Jay YANG ,  Masumi TAKI

IPC: A61K47/54 ,  C12N15/115 ,  A61P7/02

CPC classification number: A61K47/54 ,  C12N15/115 ,  A61P7/02

Abstract: Provided is a novel drug modality which at least partially overcomes the shortcomings of the conventional covalent drugs. A neutralizable covalent drug compound comprising a nucleic acid aptamer and a fluorosulfonyl group linked to the nucleic acid aptamer via a linker is provided. A composition comprising the compound and a method of producing the compound are also provided. Also provided is a neutralizable covalent drug system, comprising the compound or the composition and an oligonucleotide complementary to the nucleic acid aptamer.

公开(公告)号：US11865210B2

公开(公告)日：2024-01-09

申请号：US16216924

申请日：2018-12-11

Applicant: VECTURA INC.

Inventor： Kambiz Yadidi

IPC: A61M15/00 ,  A61K31/616 ,  A61K9/14 ,  A61P7/02 ,  A61P29/00 ,  A61K9/00

CPC classification number: A61K9/0075 ,  A61K31/616 ,  A61M15/0045 ,  A61K9/14 ,  A61M2202/064 ,  A61P7/02 ,  A61P29/00 ,  Y10T428/2982

Abstract: The subject technology relates generally to pulmonary delivery of NSAIDs, such as aspirin.

公开(公告)号：US20230398127A1

公开(公告)日：2023-12-14

申请号：US18031748

申请日：2021-10-12

Applicant: THERAMEX HQ UK LIMITED

Inventor： Mitra BOOLELL

IPC: A61K31/565 ,  A61K31/57 ,  A61K9/00 ,  A61P7/02

CPC classification number: A61K31/565 ,  A61K31/57 ,  A61K9/0053 ,  A61P7/02

Abstract: The present invention relates to the use of compositions comprising nomegestrol acetate (NOMAC) and estradiol or an ester thereof. The compositions are for use in reducing the risk of venous thromboembolism (VTE) associated with the use of combined oral contraceptives (COC). The compositions may be used in methods of contraception and/or methods of treatment in women having conditions linked to menstruation and/or fertility.

公开(公告)号：US20230372323A1

公开(公告)日：2023-11-23

申请号：US18029089

申请日：2020-09-29

Applicant: Chongqing Academy of Chinese Materia Medica

Inventor： Yong YANG ,  Yanlei GUO ,  Dajian YANG

IPC: A61K31/455 ,  A61P29/00 ,  A61P7/02

CPC classification number: A61K31/455 ,  A61P29/00 ,  A61P7/02

Abstract: The present disclosure provides a nicotinic acid derivative A with an anti-inflammation activity. The nicotinic acid derivative A has a general structural formula shown in formula (I), where R1 and R2 are different substitution sites of a main chain, and R1′ and R2′ are different substitution sites of a side chain. In the present disclosure, the nicotinic acid derivative A has desirable anti-inflammation, anti-tumor, and anti-platelet aggregation activities, and strong selectivity, and shows a remarkable clinical application value.

公开(公告)号：US11819510B2

公开(公告)日：2023-11-21

申请号：US17993770

申请日：2022-11-23

Applicant: Advanced Protein Technologies Corp.

Inventor： Kyung Ho Kim ,  Chul Soo Shin ,  Jong Won Yoon ,  Seon Min Jeon ,  Young Ha Song ,  Ok Seon Jeon

IPC: A61K31/702 ,  A61P7/02

CPC classification number: A61K31/702 ,  A61P7/02

Abstract: Disclosed are a food composition containing 2′-fucosyllactose and a pharmaceutical composition containing 2′-fucosyllactose that are effective in ameliorating, preventing or treating various cerebro-cardiovascular diseases caused by thrombogenesis, and a method for ameliorating a cerebro-cardiovascular disease caused by a thrombus by administering a composition including 2′-fucosyllactose (2′-FL) to a subject in need thereof. The 2′-fucosyllactose (2′-FL) exhibits antagonistic (inhibitory) activity against CRP and collagen, which are agonists of platelets, and thus can be used to inhibit thrombogenesis due to abnormal platelet activity.

公开(公告)号：US20230355605A1

公开(公告)日：2023-11-09

申请号：US17925750

申请日：2021-05-20

Applicant: RENASCIENCE INC.

Inventor： Toshio MIYATA

IPC: A61P11/00 ,  A61K31/47 ,  A61P7/02

CPC classification number: A61K31/47 ,  A61P7/02 ,  A61P11/00

Abstract: Provided is a drug for enhancing the fibrinolytic system, comprising a compound represented by Formula (1) or a pharmaceutically acceptable salt thereof as an active ingredient:





wherein R1 is quinolyl, R2 is halogen, and R3 is carboxyl or a group that is biologically equivalent thereto; the active ingredient being administered at a daily dosage of 120 to 300 mg, and the drug being orally administered to a patient with a disease with a clinical condition that is expected to be improved by fibrinolytic enhancement.

公开(公告)号：US11780915B2

公开(公告)日：2023-10-10

申请号：US16646554

申请日：2018-09-11

Applicant: Monash University

Inventor： Justin Hamilton ,  Mark Sleeman

IPC: C07K16/28 ,  A61K47/68 ,  A61P7/02

CPC classification number: C07K16/28 ,  A61K47/6849 ,  A61P7/02 ,  C07K2317/34 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present disclosure is directed to human protease activated receptor 4 (PAR4) binding proteins (e.g. antibodies). In particular, anti-PAR4 binding proteins which are antagonists of human PAR4, as well as methods and uses thereof.

公开(公告)号：US20230293626A1

公开(公告)日：2023-09-21

申请号：US18060529

申请日：2022-11-30

Applicant: MAIA Pharmaceuticals, Inc.

Inventor： Srikanth SUNDARAM

IPC: A61K38/10 ,  A61K9/00 ,  A61P7/02 ,  A61K47/18 ,  A61K47/12

CPC classification number: A61K38/10 ,  A61K9/0019 ,  A61P7/02 ,  A61K47/12 ,  A61K47/183

Abstract: Ready-to-use liquid bivalirudin compositions, methods of using the ready-to-use bivalirudin compositions, and methods of preparing the ready-to-use liquid bivalirudin compositions are provided herein. The liquid ready-to-use bivalirudin compositions comprise a pharmaceutically acceptable amount of bivalirudin.

公开(公告)号：US11752242B2

公开(公告)日：2023-09-12

申请号：US15735306

申请日：2016-06-10

Applicant: ATH Therapeutics Inc. ,  Attilio Difiore

Inventor： Attilio Difiore ,  Leslie Roy Berry ,  Anthony Kam Chuen Chan

IPC: A61L33/00 ,  A61L29/16 ,  A61L31/16 ,  A61K47/55 ,  A61K47/61 ,  A61L27/54 ,  A61K47/64 ,  A61P27/02 ,  A61P7/02 ,  A61K9/00 ,  A61K31/727 ,  A61K38/17

CPC classification number: A61L33/0011 ,  A61K9/0048 ,  A61K31/727 ,  A61K38/1709 ,  A61K47/55 ,  A61K47/61 ,  A61K47/64 ,  A61L27/54 ,  A61L29/16 ,  A61L31/16 ,  A61P7/02 ,  A61P27/02 ,  A61L2300/42 ,  A61L2420/02

Abstract: Medical devices, systems, and methods for treating conditions using antithrombin-heparin conjugates are disclosed. For example, medical devices can be coated with antithrombin-heparin (ATH) resulting in reduced thrombogenicity. Various conditions can likewise be treated with ATH.